1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
According to the recently published report 'Estrogen Receptor Beta - Pipeline Review, H2 2020'; Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) pipeline Target constitutes close to 20 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Estrogen receptor beta (ERB) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR2. Upon binding to 17beta-estradiol or related ligands, the encoded protein forms homo- or hetero-dimers that interact with specific DNA sequences to activate transcription.
The report 'Estrogen Receptor Beta - Pipeline Review, H2 2020' outlays comprehensive information on the Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 5, 3 and 5 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 2 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Musculoskeletal Disorders, Women's Health, Genetic Disorders, Hormonal Disorders, Immunology, Infectious Disease, Male Health and Metabolic Disorders which include indications Multiple Sclerosis, Osteoporosis, Alzheimer's Disease, Breast Cancer, Prostate Cancer, Triple-Negative Breast Cancer (TNBC), Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Bile Duct Cancer (Cholangiocarcinoma), Carcinomas, Colon Cancer, Coronavirus Disease 2019 (COVID-19), Demyelinating Diseases, Depression, Ductal Carcinoma In Situ, Endometrial Cancer, Endometriosis, Fallopian Tube Cancer, Hormone Sensitive Breast Cancer, Inflammation, Leiomyosarcoma, Male Hypogonadism, Malignant Pleural Mesothelioma, Neuromyelitis Optica (Devic’s Syndrome), Obesity, Ovarian Cancer, Peritoneal Cancer, Post Menopausal Mood Disorder, Precocious Puberty, Uterine Cancer and Vasomotor Symptoms of Menopause (Hot Flashes).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2)
- The report reviews Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Introduction
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Therapeutics Development
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Therapeutics Assessment
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Companies Involved in Therapeutics Development
(bazedoxifene acetate + cholecalciferol) - Drug Profile
acolbifene + prasterone - Drug Profile
AUS-131 - Drug Profile
dehydrodiconiferyl alcohol - Drug Profile
Drug to Agonize ER-Beta for Multiple Sclerosis - Drug Profile
erteberel - Drug Profile
estradiol - Drug Profile
fosfestrol - Drug Profile
fulvestrant - Drug Profile
fulvestrant - Drug Profile
fulvestrant - Drug Profile
KB-3944 - Drug Profile
KB-9520 - Drug Profile
Libidua - Drug Profile
Loseasonique - Drug Profile
NDC-1308 - Drug Profile
Small Molecule to Agonize ESR2 for Obesity and Depression - Drug Profile
Small Molecule to Agonize ESR2 for Oncology - Drug Profile
Small Molecules to Agonize ESR2 for Multiple Sclerosis - Drug Profile
Small Molecules to Agonize Estrogen Beta Receptor for Inflammatory Diseases and Oncology - Drug Profile
SR-16234 - Drug Profile
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Product Development Milestones
Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca Plc
- Atossa Therapeutics Inc
- Avivia BV
- Eagle Pharmaceuticals Inc
- Eli Lilly and Co
- Endece LLC
- EndoCeutics Inc
- Helixmith Co Ltd
- Huons Co Ltd
- Karo Pharma AB
- Kissei Pharmaceutical Co Ltd
- MEI Pharma Inc
- Oasmia Pharmaceutical AB